Clinicopathological features and menin expression of pancreatic neuroendocrine neoplasm associated with multiple endocrine neoplasia type 1

与多发性内分泌肿瘤 1 型相关的胰腺神经内分泌肿瘤的临床病理特征和脑膜蛋白表达

阅读:6
作者:Akari Sonoda, Yo-Ichi Yamashita, Tatsuya Kondo, Hiromitsu Hayashi, Katsunori Imai, Takaaki Higashi, Kensuke Yamamura, Takanobu Yamao, Daisuke Hashimoto, Hideo Baba

Conclusion

M-pNEN patients tend to develop spatially and temporally multifocal pNENs. However, M-pNEN patient prognosis is good with repeated surgeries at recurrence. Therefore, minimal resection with strict follow-up is recommended rather than extensive pancreatic resections for consideration of recurrence in M-pNEN.

Methods

Seventy-seven patients who underwent resection of pNEN at our department from January 2001 to December 2017 were retrospectively analyzed. Immunohistochemical analysis of menin was performed using resected specimens.

Purpose

We examined therapeutic strategies for pancreatic neuroendocrine neoplasm (pNEN) associated with MEN1 (M-pNEN) by investigating clinicopathological features and menin expression.

Results

Seven patients (9%) met the diagnostic criteria for MEN1. M-pNEN had more tumors (P < .01), a higher recurrence rate (P = .028), and higher residual pancreatic recurrence (P < .01) than sporadic pNEN (S-pNEN). There were no significant differences in tumor size, lymph node metastasis, or World Health Organization grade between the two groups. Reduced menin staining in the tumor nuclei was found in 86% of M-pNEN; whereas only 34% of S-pNEN showed decreased nuclear staining. The remainder (66%) showed strong nuclear staining similar to normal islet cells (P = .0071). Furthermore, four patients (57%) with MEN1 had many microadenomas with reduced nuclear menin staining. Overall survival of M-pNEN patients was significantly better than S-pNEN patients (P = .049).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。